Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research AgendaPR Newswire·Oct 14, 2026 at 08:07 AMONCY-9.04%RVMD-5.97%
Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment | ONCY Stock NewsStockTitan·Oct 14, 2026 at 05:30 AMONCY-9.04%
Oncolytics Biotech says new pelareorep cancer immunotherapy method-of-use patent issues in several countriesPUBT·Oct 12, 2026 at 08:06 PMONCY-9.04%
Weekly Recap | Oncolytics Biotech -11.73%, hitting a one-month lowWeekly Review·Oct 10, 2026 at 07:22 AMONCY-9.04%
Cross-Border Playbooks: How Healthcare and Chip Firms Outmaneuver 2026's Regulatory MazeGlobal Report·Oct 6, 2026 at 10:16 AMHSIC-0.70%VEEV-0.85%
Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy | ONCY Stock NewsStockTitan·Sep 29, 2026 at 05:30 AMONCY-9.04%
